U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428538) titled 'Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)' on Feb. 19.
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.
Study Start Date: Jan. 29
Study Type: INTERVENTIONAL
Condition:
Hepatitis
Intervention:
DRUG: Larsucosterol
Larsucost...